<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bipolar disorder in women: Contraception and preconception assessment and counseling
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bipolar disorder in women: Contraception and preconception assessment and counseling
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bipolar disorder in women: Contraception and preconception assessment and counseling
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Victoria Hendrick, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H20268725">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prepregnancy counseling is relevant to all female patients with bipolar disorder who are of reproductive age, regardless of their plans regarding pregnancy [
         <a href="#rid1">
          1
         </a>
         ]. Unplanned pregnancies are common in the general population, and the risk of unplanned pregnancies appears to be greater in women with bipolar disorder than in healthy controls [
         <a href="#rid2">
          2
         </a>
         ]. Contraception should be encouraged for patients who wish to avoid pregnancy, and patients who consider becoming pregnant should receive preconception counseling about the risks to the patient and her child.
        </p>
        <p>
         This topic reviews contraception and the preconception assessment and counseling of women with bipolar disorder. Indications for maintenance pharmacotherapy during pregnancy, selecting preconception and prenatal maintenance treatment for bipolar patients, and the teratogenic and postnatal effects of medications used for bipolar disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/82834.html" rel="external">
          "Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1029028">
         <span class="h1">
          DEFINITION OF BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1866827">
         <span class="h1">
          CONTRACEPTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We discuss family planning desires and contraceptive need with all women of reproductive potential. Information to guide the selection of contraception in women with mood and other medical disorders is available through the World Health Organization
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=15701" target="_blank">
          Medical Eligibility Criteria
         </a>
         and the United States Centers for Disease Control
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYAmCahKbgv18S9Zgv5fBNxTGoMdTGRC8XnfLV%2BmDF%2FKgq%2FUbcwPNhHygS%2BUPWWe15o2kSqIPMCtrmL2KJwaUlwQ%3D&amp;TOPIC_ID=15701" target="_blank">
          US Medical Eligibility Criteria for Contraceptive Use
         </a>
         . While the guidelines are generally similar, the clinician should use the one that best matches the population.
        </p>
        <p class="headingAnchor" id="H3873625663">
         <span class="h2">
          Unmet contraceptive need
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small studies suggest that women with bipolar disorder are characterized by suboptimal use of contraception, lower levels of family planning, and higher rates of unintended pregnancy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a survey of 136 female patients receiving maintenance pharmacotherapy (including drugs that appear to be teratogenic), 41 percent did not use birth control [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Studies comparing euthymic, reproductive-age women with bipolar disorder to matched healthy control women reported women with bipolar disorder were three times more likely to have an unintended pregnancy or be ambivalent about pregnancy [
         <a href="#rid2">
          2,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2853750019">
         <span class="h2">
          Approach to contraceptive selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the patient ultimately selects her contraceptive method, we take the following approach to thinking about contraception in women with bipolar disorder:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who desire the most effective contraception or durable contraception, we discuss long-acting reversible contraceptives (LARCs), including the
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper intrauterine device
         </a>
         (IUD), levonorgestrel-releasing IUDs, and the
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). These methods require minimal user action, have failure rates of less than 1 percent, have high continuation rates in this population, and last from 3 to 12 years, depending on the device. In particular, the copper IUD contains no hormones, does not interfere with concurrent medications, and maintains efficacy for up to 12 years, although it may make menstrual bleeding heavier. While data regarding progestin-releasing IUDs or implants in women with bipolar disorder are limited, use of these products does not appear to worsen mood or increase the risk of hospitalization, and both generally lessen menstrual flow [
         <a href="#rid6">
          6,7
         </a>
         ]. (See
         <a class="local">
          'Impact of hormonal contraception on mood'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         LARC methods are similar in efficacy to sterilization but have no surgical risk. However, for women who do not desire future fertility, surgical sterilization (male or female) is a reasonable option. General principles of contraceptive selection and the attributes of various contraceptive methods are presented separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/101560.html" rel="external">
          "Overview of female permanent contraception"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8094.html" rel="external">
          "Vasectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who do not find LARC methods acceptable or desire contraception for a only short timeframe, we discuss hormonal contraception, including combined estrogen-progestin products (oral pills, transdermal patch, and vaginal rings) and progestin-only methods (depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [DMPA] injections and progestin-only oral pills). These methods are effective when used correctly and consistently, although they are not as effective as LARC  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). Concerns for these methods include need for regular action on the part of the user and higher discontinuation rates in this population [
         <a href="#rid7">
          7
         </a>
         ]. Mood and medication interactions are reviewed below. (See
         <a class="local">
          'Impact of hormonal contraception on mood'
         </a>
         below and
         <a class="local">
          'Potential drug interactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More information on each contraceptive method is reviewed in detail separately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who desire contraception only at the time of vaginal intercourse, we discuss pericoital and barrier contraceptives. Pericoital contraception includes the single-size diaphragm (commercial name Caya) with spermicide, cervical cap (where available) with spermicide, and the spermicide-containing contraceptive sponge. Barrier methods include male and female condoms. Major limitations of these methods include lower efficacy compared with the above methods and need for patient-directed use with every act of intercourse  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women who require emergency contraception are candidates for any of the available options [
         <a href="#rid8">
          8
         </a>
         ]. The
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         is the most effective method, does not impact mood, and provides ongoing contraception. While not specifically studied in women with bipolar disorder, the hormone-based emergency contraceptives (
         <a class="drug drug_general" data-topicid="15626" href="/z/d/drug information/15626.html" rel="external">
          ulipristal
         </a>
         acetate and
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         ) are short-acting, and complications with use in this population have not been reported. (See
         <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">
          "Emergency contraception"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women at risk of sexually transmitted infection are advised about consistent condom use (male or female) even if other contraceptive methods are being used. (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1809668223">
         <span class="h2">
          Impact of hormonal contraception on mood
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although supporting data are limited, hormonal methods of contraception do not appear to increase the risk of hospitalization for mood exacerbations in women with bipolar disorder, and one small study reported mood stabilization in women treated with
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         [
         <a href="#rid6">
          6,7,9
         </a>
         ]. However, studies of progestins in other populations have reported possible negative effects on mood, so we advise women who desire hormonal contraceptives to track their symptoms and have close follow-up [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Of note, use of the estrogen receptor antagonist
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         can be effective for mania [
         <a href="#rid11">
          11
         </a>
         ]; this antimanic effect is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Other options'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1866834">
         <span class="h2">
          Potential drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticonvulsant medications, including
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , induce hepatic enzymes and increase the metabolism of hormonal contraceptives, which in turn decreases contraceptive efficacy [
         <a href="#rid12">
          12
         </a>
         ]. Thus, we, along with other experts, advise women with bipolar disorder who are treated with carbamazepine to avoid combined estrogen-progestin contraception (oral pills, transdermal patch, and vaginal ring) and progestin-only pills, and instead choose an IUD,
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         , or
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         injection [
         <a href="#rid8">
          8,12
         </a>
         ]. Carbamazepine use does not appear to lessen DMPA and etonogestrel implant efficacy because these methods provide continuous hormone exposure above the threshold required for ovulation suppression, although supporting data are limited. The hormone effect of the levonorgestrel-releasing IUDs is mainly local within the uterus and not impacted by alterations in hepatic enzymes. Additional information about the interaction of carbamazepine and hormonal contraception is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults", section on 'Contraception'
         </a>
         .)
        </p>
        <p>
         However, hormonal contraception may be acceptable for some women who also require
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . For situations where a LARC method is not appropriate or declined, or the patient has other medical indications for hormonal contraceptive use (eg, heavy menstrual bleeding), the use of a combined hormonal or progestin-only method affords better protection from unintended pregnancy than no contraception at all. Women who desire oral estrogen-progestin pills may benefit from 24/4 dosing regimens rather than the traditional 21/7 approach because 24/4 products have fewer hormone-free days, although supporting data are not available. Women who elect to use hormonal contraception and carbamazepine are also counseled on the regular use of condoms (male or female) to provide additional contraception. Detailed information about carbamazepine and hormonal contraception failure is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults", section on 'Contraception'
         </a>
         .)
        </p>
        <p>
         Women who require
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         are also advised to avoid estrogen-containing contraceptives because estrogen increases lamotrigine clearance, and thus reduces its efficacy for treating bipolar disorder [
         <a href="#rid13">
          13
         </a>
         ]. However, for women who desire combined estrogen-progestin methods either for contraception or treatment of other medical disorders, a reasonable alternative approach is to prescribe higher doses of lamotrigine. Additional information about drug-drug interactions between lamotrigine and combined hormonal contraception is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1866121">
         <span class="h1">
          PRECONCEPTION ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical assessment of bipolar patients who consider becoming pregnant includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests [
         <a href="#rid14">
          14-16
         </a>
         ]. The general preconception evaluation for all patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/448.html" rel="external">
          "The preconception office visit", section on 'Risk assessment at the preconception office visit'
         </a>
         .)
        </p>
        <p>
         The psychiatric history for bipolar patients should emphasize the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – Women should be aware that fertility declines and the risk of fetal chromosomal abnormalities rises with increasing age, especially after the mid-30s.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Weight
         </strong>
         – Many female bipolar patients are obese, which increases the risk of pregnancy complications (eg, gestational diabetes, preeclampsia, cesarean delivery, and fetal neural tube defects) [
         <a href="#rid17">
          17
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/433.html" rel="external">
          "Obesity in pregnancy: Complications and maternal management"
         </a>
         ). Clinicians should encourage patients to conceive at a normal body mass index (BMI), which is calculated from height and weight (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 1
         </a>
         ). Weight loss for overweight patients with dietary therapy, exercise, and other treatments is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Current status of bipolar disorder and course of illness
         </strong>
         – Clinicians should assess current symptoms of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ); number of prior mood episodes, particularly during the previous two to five years; and history of psychotic features (delusions and/or hallucinations) and suicidal and homicidal ideation and behavior. Bipolar patients are encouraged to delay pregnancy until their illness is stable, and a long (eg, ≥2 years) duration of euthymia prior to conception is preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – Several medications used to treat bipolar disorder appear to be teratogenic, including
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and to a lesser extent
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supplements
         </strong>
         – Many patients do not realize that herbal supplements are potentially harmful to the fetus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Substance abuse
         </strong>
         – Drug, alcohol, and nicotine abuse is widespread among bipolar patients. Women with bipolar disorder should be screened for substance use disorders, educated about the potential impact on the baby, and offered substance abuse treatment; these issues are discussed separately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features", section on 'Substance use disorders'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">
          "Substance use during pregnancy: Screening and prenatal care"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">
          "Alcohol use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">
          "Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/106878.html" rel="external">
          "Stimulant use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">
          "Stimulant use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial functioning
         </strong>
         – Psychosocial stressors (eg, domestic violence, marital conflict, inadequate social support, and financial problems) are likely to disrupt the patient’s stability and should be addressed before pregnancy
        </p>
        <p>
        </p>
        <p>
         The general medical history should emphasize the metabolic syndrome and diabetes, which commonly occur in bipolar patients and should be stabilized prior to attempting conception [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37198185">
         <span class="h1">
          FERTILITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar patients may have more difficulty conceiving than individuals without the disorder, but this is not established [
         <a href="#rid18">
          18
         </a>
         ]. One review found that fertility rates are lower among patients with bipolar disorder than individuals without the disorder [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         It is not known if ovulatory function in bipolar patients is impaired, as reflected by menstrual difficulties, due to conflicting results across studies. A retrospective study found that patients who had yet to start pharmacotherapy (n = 295) were more likely to report menstrual cycle irregularities than controls (n = 619; 34 versus 22 percent) [
         <a href="#rid13">
          13
         </a>
         ]. However, another study that assessed patients with bipolar disorder (n = 103) and controls (n = 36) found that the rates of menstrual abnormalities were comparable [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Menstrual cycle irregularities in some bipolar patients are due to medications, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antipsychotics
         </strong>
         – Antipsychotics can increase prolactin levels, which can result in oligomenorrhea or amenorrhea and galactorrhea. Although hyperprolactinemia is more likely to occur with either
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         or first-generation antipsychotics, it has also been reported with other second-generation antipsychotics, such as
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         [
         <a href="#rid13">
          13,21-23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Valproate
         </strong>
         –
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
         use has been linked with polycystic ovarian syndrome (menstrual irregularities and hyperandrogenism) in bipolar patients [
         <a href="#rid13">
          13,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Assessing menstrual cycle patterns before starting antipsychotics or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         can help determine if medications are causing menstrual abnormalities that are observed after starting the drugs. Additional information about the evaluation, causes, and treatment of infertility is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7396.html" rel="external">
          "Overview of infertility"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37198208">
         <span class="h1">
          PRECONCEPTION AND PRENATAL PHARMACOTHERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For bipolar patients who plan to or do become pregnant, we suggest maintenance pharmacotherapy. (See
         <a class="medical medical_review" href="/z/d/html/82834.html" rel="external">
          "Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37198399">
         <span class="h1">
          RISKS ASSOCIATED WITH PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although pregnancy in bipolar patients is associated with several risks, bipolar disorder is not a contraindication for pregnancy [
         <a href="#rid25">
          25
         </a>
         ]. We encourage clinicians to include the spouse when discussing these risks with the patient, as well as other family members who may be called upon to support the patient during and after the pregnancy.
        </p>
        <p class="headingAnchor" id="H1267336">
         <span class="h2">
          Risk of maternal mood episodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians should describe the risk of suffering bipolar mood episodes during pregnancy. As an example, a retrospective study in parous women with bipolar I disorder (n = 980) found that perinatal mood episodes had occurred in 56 percent, and among parous bipolar II patients, 40 percent [
         <a href="#rid26">
          26
         </a>
         ]. Clinicians should also explain that pharmacotherapy may reduce this risk. In addition, clinicians, patients, and family members are encouraged to develop prespecified contingency plans for treating mood episodes that occur during pregnancy [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H317070">
         <span class="h3">
          Relapse during pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although bipolar patients often suffer mood episodes during pregnancy, it is not known if pregnancy changes the risk of recurrence. Some patients may experience fewer recurrences during pregnancy [
         <a href="#rid27">
          27
         </a>
         ], whereas the course of illness in other pregnant patients remains unchanged or worsens [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         In two retrospective studies of pregnant bipolar patients, recurrent mood episodes occurred in 5 and 23 percent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study in pregnant patients (n = 436) found that recurrent mood episodes occurred in 5 percent [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study (n = 1120), recurrences during pregnancy were observed in 23 percent of patients [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         For pregnant bipolar patients, the risk of recurrence appears to be greatest during the first trimester. In a prospective observational study of 63 patients who suffered a mood episode, the timing was as follows [
         <a href="#rid28">
          28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First trimester – 66.6 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second trimester – 23.8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third trimester – 9.5 percent
        </p>
        <p>
        </p>
        <p>
         The most common morbidity in pregnant bipolar patients is major depression [
         <a href="#rid31">
          31,32
         </a>
         ]. In a prospective observational study of 81 mood episodes, the polarity was [
         <a href="#rid28">
          28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major depression – 42 percent of episodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed (concurrent symptoms of major depression and mania/hypomania) – 32 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mania or hypomania – 26 percent
        </p>
        <p>
        </p>
        <p>
         This finding is consistent with the observation that depression is the predominant mood state for bipolar patients in general [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         Clinical factors that may be associated with relapse during pregnancy include [
         <a href="#rid28">
          28,32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shorter period of clinical stability prior to conception
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discontinuing pharmacotherapy between six months prior to conception and 12 weeks after conception
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unplanned pregnancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current psychiatric comorbidity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lifetime duration of bipolar disorder ≥5 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of at least one recurrent mood episode per year following onset of bipolar disorder
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H317273">
         <span class="h4">
          Relapse after discontinuing pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintenance treatment during pregnancy may protect bipolar patients against recurrent mood episodes [
         <a href="#rid32">
          32
         </a>
         ]. In a prospective observational study, euthymic pregnant patients who either continued (n = 27) or discontinued (n = 62) pharmacotherapy were followed through the end of pregnancy [
         <a href="#rid28">
          28
         </a>
         ]. Maintenance medications included
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and antidepressants, with some patients taking more than one drug. Among the results:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relapse occurred in fewer patients who continued pharmacotherapy than patients who stopped pharmacotherapy (37 versus 86 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The proportion of time spent ill with a mood episode during pregnancy was less in patients who continued pharmacotherapy than patients who stopped pharmacotherapy (9 versus 43 percent of weeks)
        </p>
        <p>
        </p>
        <p>
         Indications for maintenance pharmacotherapy during pregnancy, and selecting preconception and prenatal maintenance treatment for bipolar patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/82834.html" rel="external">
          "Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         .)
        </p>
        <p>
         Recurrence of bipolar mood episodes in pregnant patients appears to be greater if medications are quickly discontinued [
         <a href="#rid29">
          29
         </a>
         ]. In a prospective observational study of 62 patients who discontinued pharmacotherapy, the median time to recurrence was shorter if medications were discontinued in less than 15 days, compared with tapering and stopping medications over 15 or more days (2 versus 22 weeks) [
         <a href="#rid28">
          28
         </a>
         ]. This finding is consistent with other studies that have found that recurrence is more likely if stable maintenance pharmacotherapy for bipolar disorder is terminated over 1 to 14 days, compared with a more gradual taper [
         <a href="#rid35">
          35-37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H43784839">
         <span class="h3">
          Postpartum mood episodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of bipolar mood episodes appears to be greater in the postpartum period than during pregnancy. A retrospective study of 1120 pregnancies in bipolar patients found that mood episodes occurred more than twice as often in the postpartum period (six months following live births) than during pregnancy [
         <a href="#rid31">
          31
         </a>
         ]. A second retrospective study of 700 perinatal events in bipolar I patients found that more than 90 percent occurred in the postpartum period [
         <a href="#rid26">
          26
         </a>
         ]. Additional information about the risk of postpartum mood episodes is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14651.html" rel="external">
          "Bipolar disorder in postpartum women: Epidemiology, clinical features, assessment, and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5861817">
         <span class="h2">
          Congenital defects in offspring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The base rate for congenital defects in the offspring of patients with bipolar disorder appears to be no different than that of the general population, which is 2 to 5 percent [
         <a href="#rid38">
          38-42
         </a>
         ]. Although one study found that bipolar disorder was associated with congenital anomalies, the study did not account for the use of psychotropic drugs [
         <a href="#rid43">
          43
         </a>
         ]. Some medications that are used to treat bipolar disorder appear to be teratogenic, including
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and to a lesser extent
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         .
        </p>
        <p>
         The increased risk of malformations and adverse postnatal developmental effects due to treatment of bipolar disorder during pregnancy is discussed separately, as are the general principles of teratology.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">
          "Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/100334.html" rel="external">
          "Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2940.html" rel="external">
          "Congenital anomalies: Approach to evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13363306">
         <span class="h2">
          Risk of pregnancy complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse pregnancy and birth outcomes may occur more often in women with bipolar disorder regardless of treatment status, compared to women without bipolar disorder. A national registry study compared outcomes in pregnant bipolar patients who were treated with antipsychotics,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and/or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         (n = 320), pregnant bipolar patients who were not treated with these drugs (n = 554), and pregnant women without bipolar disorder who did not receive these drugs (n = 331,263) [
         <a href="#rid42">
          42
         </a>
         ]. The analyses, which controlled for potential confounders such as maternal age and substance use disorders, found that:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induced or planned caesarean delivery occurred in more treated and untreated bipolar patients than women without bipolar disorder (38 and 31 versus 21 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preterm birth occurred in more treated and untreated bipolar patients than women without bipolar disorder (8 and 8 versus 5 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse pregnancy and birth outcomes were comparable for treated and untreated bipolar patients
        </p>
        <p>
        </p>
        <p>
         In addition, a study of an administrative dataset included pregnant women with bipolar disorder (n &gt;1800) and pregnant women with no mental illness (n &gt;432,000), and found that bipolar disorder was associated with preterm birth (odds ratio 2.0, 95% CI 1.7-2.3) and severe large for gestational age birthweight (&gt;97
         <sup>
          th
         </sup>
         percentile; odds ratio 1.3, 95% CI 1.1-1.5) [
         <a href="#rid43">
          43
         </a>
         ]. Although the analyses controlled for several potential confounds (eg, maternal age and gestational hypertension and diabetes), the study did not control for other factors (eg, psychotropic drug use).
        </p>
        <p class="headingAnchor" id="H1865891">
         <span class="h2">
          Prenatal infections and bipolar disorder in offspring
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is not known if in utero exposure to infectious agents is a risk factor for developing bipolar disorder, due to conflicting results across observational studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Toxoplasma gondii
          </em>
         </strong>
         – Three studies suggest that prenatal exposure to
         <em>
          Toxoplasma gondii
         </em>
         is associated with bipolar disorder in the offspring, whereas a fourth study found no association:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One study found that seropositivity to
         <em>
          Toxoplasma gondii
         </em>
         antibodies was higher in bipolar patients (n = 110) than healthy controls (n = 106; 77 versus 48 percent) [
         <a href="#rid44">
          44
         </a>
         ], and a second study also found elevated antibodies in bipolar patients (n = 54) compared with controls (n = 314; odds ratio 2) [
         <a href="#rid45">
          45
         </a>
         ]. In a third study that identified bipolar individuals (n = 41) in a nationally representative sample from the United States,
         <em>
          Toxoplasma gondii
         </em>
         seroprevalence was associated with bipolar disorder (odds ratio 2) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, one study compared 127 bipolar patients and 127 matched controls for antibodies to
         <em>
          Toxoplasma gondii
         </em>
         in blood drawn within one week of birth, and found no association between neonatal seropositivity and an increased risk of bipolar disorder [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Influenza
         </strong>
         – A study compared 92 adult bipolar patients and 722 matched controls for in utero exposure to influenza (based upon clinical diagnoses of mothers), and found that gestational exposure to influenza at any time during pregnancy was four times greater in offspring with bipolar disorder, compared with controls [
         <a href="#rid48">
          48
         </a>
         ]. In a subsequent study that used the same dataset, exposure to influenza was based upon maternal serologies; the second study found no increase in risk of bipolar disorder among offspring of mothers with serologic documentation of influenza exposure [
         <a href="#rid49">
          49
         </a>
         ]. However, both studies found that in utero exposure to influenza was associated with a five- to sixfold greater risk of bipolar disorder with psychotic features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Onset of bipolar disorder does not appear to be associated with exposure to cytomegalovirus [
         <a href="#rid45">
          45,47
         </a>
         ] or to herpes simplex virus type 1 and 2 [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H136820198">
         <span class="h2">
          Obstetric complications and bipolar disorder in offspring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obstetrical complications do not appear to play a role in the pathogenesis of bipolar disorder:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of eight observational studies found that exposure to obstetric complications (eg, maternal anemia, rubella, prematurity, prolonged labor, and neonatal respiratory problems) was comparable for bipolar patients (n = 272) and healthy controls (n = 331; 31 versus 29 percent) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a subsequent retrospective study that compared 120 bipolar patients with 98 healthy controls, difficulties during delivery (eg, breech delivery, cesarean section, cord around the neck, and labor &gt;24 hours) were comparable for patients and controls (66 and 57 percent) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A national registry study found that in bipolar patients (n = 724) and matched controls without bipolar disorder or psychotic disorder (n = 1419), exposure to obstetric complications (uterine bleeding, maternal hypertension, breech presentation, forceps delivery, emergency cesarean section, induced labor, and neonatal monitoring or intensive care) was comparable, after adjusting for maternal factors such as age, education, number of previous births, psychiatric history, and smoking [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, a national registry study found an association between preterm birth and increased risk of hospitalization in adulthood for bipolar disorder, which occurred in a monotonic manner [
         <a href="#rid53">
          53
         </a>
         ]. Compared to adults with term births:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults born at 32 to 36 weeks were three times more likely to have bipolar disorder (hazard ratio 3, 95% CI 2-5)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults born at less than 32 weeks gestation were seven times more likely to have bipolar disorder (hazard ratio 7, 95% CI 3-21)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H37197964">
         <span class="h2">
          Risk of child inheriting psychopathology
         </span>
        </p>
        <p class="headingAnchor" id="H13362983">
         <span class="h3">
          Bipolar disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar patients who consider having children typically want information about the risk that offspring will inherit bipolar disorder. Suggestions for prenatal psychiatric genetic counseling are discussed in the tables  (
         <a class="graphic graphic_table graphicRef115756" href="/z/d/graphic/115756.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef115757" href="/z/d/graphic/115757.html" rel="external">
          table 5
         </a>
         ). Although patients may benefit from specialist psychiatric genetic counseling [
         <a href="#rid54">
          54
         </a>
         ], this service is often not available.
        </p>
        <p>
         The genetics of bipolar disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/678.html" rel="external">
          "Bipolar disorder in adults: Epidemiology and pathogenesis", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6188971">
         <span class="h3">
          Other disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         The offspring of bipolar parents typically inherit psychopathology other than bipolar disorder, including [
         <a href="#rid55">
          55-65
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Schizophrenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Schizoaffective disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unipolar major depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Substance use disorders
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oppositional defiant disorder and conduct disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disruptive mood dysregulation disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attention deficit hyperactivity disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety disorders
        </p>
        <p>
        </p>
        <p>
         As an example, an observational study followed 108 offspring with at least one bipolar parent for up to 12 years, from adolescence (mean age at study intake 17 years) to adulthood [
         <a href="#rid66">
          66
         </a>
         ]. Among the offspring, the lifetime prevalence of at least one psychiatric diagnosis was 72 percent. However, a diagnosis of bipolar I disorder, bipolar II disorder, or cyclothymic disorder was made in only 13 percent. By contrast, the lifetime prevalence of anxiety disorders, substance use disorders, and unipolar major depression was 25, 23, and 17 percent.
        </p>
        <p class="headingAnchor" id="H2390983813">
         <span class="h2">
          Risk of developmental disorders in offspring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal bipolar disorder may not be associated with developmental disorders in the offspring. A prospective observational study included offspring of women with prenatal bipolar disorder who were not treated with psychotropic medications (n = 27), and offspring of women who did not have bipolar disorder and were not treated with psychotropic medications (n = 116) [
         <a href="#rid67">
          67
         </a>
         ]. Assessments of the infants at age one year found that neuromotor, cognitive, and behavioral functioning were comparable for the two groups.
        </p>
        <p class="headingAnchor" id="H1867394">
         <span class="h2">
          Reducing risks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy outcomes may be improved in bipolar patients who:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Achieve clinical stability prior to conception
         </strong>
         – For bipolar patients who want to conceive, we suggest that they wait until they are clinically stable for at least 6 to 24 months [
         <a href="#rid25">
          25
         </a>
         ]. A prospective observational study of 89 pregnant bipolar patients found that a short period of clinical stability between the most recent mood episode and conception was associated with recurrent mood episodes during pregnancy [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use
         </strong>
         <strong>
          folic acid
         </strong>
         –
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         is recommended for all women planning to conceive and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/423.html" rel="external">
          "Preconception and prenatal folic acid supplementation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/453.html" rel="external">
          "Nutrition in pregnancy: Dietary requirements and supplements", section on 'Folate/folic acid'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">
          "Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Folic acid supplementation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other preconception interventions that can reduce risks to a woman’s pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/448.html" rel="external">
          "The preconception office visit", section on 'Interventions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13497966">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (See
         <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">
          "Patient education: Bipolar disorder (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (See
         <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">
          "Patient education: Bipolar disorder (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These educational materials can be used as part of psychoeducational psychotherapy. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'
         </a>
         .)
        </p>
        <p>
         The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=15701" target="_blank">
          the website
         </a>
         or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.
        </p>
        <p>
         More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).
        </p>
        <p>
         The Depression and Bipolar Support Alliance (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=15701" target="_blank">
          the website
         </a>
         or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.
        </p>
        <p>
         The National Alliance on Mental Illness (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=15701" target="_blank">
          the website
         </a>
         or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.
        </p>
        <p class="headingAnchor" id="H1029020">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Definition of bipolar disorder'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar patients who want to avoid pregnancy should receive information about contraception, especially long-acting reversible contraceptives. Antiepileptics that are used to treat bipolar disorder may interact with hormonal contraception.
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         may render oral contraceptives ineffective, and conversely, oral contraceptives that include estrogen may reduce the effectiveness of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         . (See
         <a class="local">
          'Contraception'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical assessment of bipolar patients who consider becoming pregnant includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests. The psychiatric history should emphasize age, body mass index (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 1
         </a>
         ), current clinical status of bipolar disorder and course of illness, medications, supplements, substance abuse, and psychosocial functioning. (See
         <a class="local">
          'Preconception assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar patients may have more difficulty conceiving than individuals without the disorder, but this is not established. Antipsychotics and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         can cause ovulatory dysfunction. (See
         <a class="local">
          'Fertility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Euthymic bipolar patients often receive maintenance pharmacotherapy prior to conception and during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Up to 70 percent of pregnant bipolar patients suffer at least one mood episode during pregnancy, but it is not known if pregnancy changes the risk of recurrence. The risk of recurrence appears to be greatest during the first trimester, and the most common morbidity is major depression. Risk factors for recurrence include a shorter period of clinical stability prior to conception, discontinuing pharmacotherapy (especially if medications are tapered and stopped in less than 15 days), unplanned pregnancy, current psychiatric comorbidity, lifetime duration of bipolar disorder ≥5 years, and history of at least one recurrent mood episode per year following onset of bipolar disorder. (See
         <a class="local">
          'Relapse during pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse pregnancy and birth outcomes appear to be more common in women with bipolar disorder regardless of treatment status, compared to women without bipolar disorder. (See
         <a class="local">
          'Risk of pregnancy complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The base rate for congenital defects in the offspring of patients with bipolar disorder appears to be no different than that of the general population, which is two to five percent. However, some medications used to treat bipolar disorder appear to be teratogenic, including
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and to a lesser extent
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder aggregates within families and there is evidence that genes are involved in the pathogenesis of the disorder. The estimated prevalence of bipolar disorder in children of families with one bipolar parent is 9 percent, whereas the rate in the general population is 1 to 2 percent. (See
         <a class="local">
          'Bipolar disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, the offspring of bipolar parents may inherit schizophrenia, schizoaffective disorder, unipolar major depressive disorder, substance use disorders, oppositional defiant disorder, conduct disorder, attention deficit hyperactivity disorder, and anxiety disorders. (See
         <a class="local">
          'Other disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy outcomes may be improved in bipolar patients who achieve clinical stability prior to conception and use
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         . (See
         <a class="local">
          'Reducing risks'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet 2014; 384:1789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marengo E, Martino DJ, Igoa A, et al. Unplanned pregnancies and reproductive health among women with bipolar disorder. J Affect Disord 2015; 178:201.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magalhães PV, Kapczinski F, Kauer-Sant'Anna M. Use of contraceptive methods among women treated for bipolar disorder. Arch Womens Ment Health 2009; 12:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zengin Eroglu M, Lus MG. Impulsivity, Unplanned Pregnancies, and Contraception Among Women with Bipolar Disorder. Neuropsychiatr Dis Treat 2020; 16:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagano HP, Zapata LB, Berry-Bibee EN, et al. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception 2016; 94:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berenson AB, Asem H, Tan A, Wilkinson GS. Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. Obstet Gynecol 2011; 118:1331.
          </a>
         </li>
         <li class="breakAll">
          Medical eligibility criteria for contraceptive use. Fifth Edition. World Health Organization. August 2015. www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/ (Accessed on May 22, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulkarni J, Berk M, Wang W, et al. A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology 2014; 43:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fruzzetti F, Fidecicchi T. Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice. Clin Drug Investig 2020; 40:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palacios J, Yildiz A, Young AH, Taylor MJ. Tamoxifen for bipolar disorder: Systematic review and meta-analysis. J Psychopharmacol 2019; 33:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joffe H. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. J Clin Psychiatry 2007; 68 Suppl 9:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).
         </li>
         <li class="breakAll">
          Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasgon NL, Kenna HA, Reynolds-May MF, et al. Metabolic dysfunction in women with bipolar disorder: the potential influence of family history of type 2 diabetes mellitus. Bipolar Disord 2010; 12:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams KE, Marsh WK, Rasgon NL. Mood disorders and fertility in women: a critical review of the literature and implications for future research. Hum Reprod Update 2007; 13:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grover S, Nehra R, Thakur A. Bipolar affective disorder and its impact on various aspects of marital relationship. Ind Psychiatry J 2017; 26:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds-May MF, Kenna HA, Marsh W, et al. Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls. Bipolar Disord 2014; 16:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lusskin SI, Cancro R, Chuang L, Jacobson J. Prolactin elevation with ziprasidone. Am J Psychiatry 2004; 161:1925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barata PC, Santos MJ, Melo JC, Maia T. Olanzapine-Induced Hyperprolactinemia: Two Case Reports. Front Pharmacol 2019; 10:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Li H, Li S, Zou X. Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2016; 202:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kameg BN. Bipolar disorder: Treatment strategies for women of childbearing age. Perspect Psychiatr Care 2021; 57:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Florio A, Forty L, Gordon-Smith K, et al. Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry 2013; 70:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens AWMM, Goossens PJJ, Knoppert-van der Klein EAM, et al. Risk of recurrence of mood disorders during pregnancy and the impact of medication: A systematic review. J Affect Disord 2019; 249:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilden J, Poels EMP, Lambrichts S, et al. Bipolar episodes after reproductive events in women with bipolar I disorder, A study of 919 pregnancies. J Affect Disord 2021; 295:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Tondo L, Koukopoulos AE, et al. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry 2011; 168:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008; 10:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 1997; 154:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.
          </a>
         </li>
         <li class="breakAll">
          CDC. Update on Overall Prevalence of Major Birth Defects --- Atlanta, Georgia, 1978--2005 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm (Accessed on May 24, 2011).
         </li>
         <li class="breakAll">
          New York State Department of Health (2010). Congenital Malformations Registry Summary Report, Statistical Summary of Children Born in 2006 and Diagnosed Through 2008. http://www.health.ny.gov/ (Accessed on December 26, 2011).
         </li>
         <li class="breakAll">
          Swedish National Board of Health and Welfare, Center for Epidemiology (2004). Registration of Congenital Malformations in the Swedish Health Registers, 1995-2001. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/10350/2004-112-1_20041121.pdf (Accessed on December 26, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodén R, Lundgren M, Brandt L, et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 2012; 345:e7085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mei-Dan E, Ray JG, Vigod SN. Perinatal outcomes among women with bipolar disorder: a population-based cohort study. Am J Obstet Gynecol 2015; 212:367.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord 2013; 148:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickerson F, Stallings C, Origoni A, et al. Antibodies to Toxoplasma gondii in individuals with mania. Bipolar Disord 2014; 16:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearce BD, Kruszon-Moran D, Jones JL. The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol Psychiatry 2012; 72:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortensen PB, Pedersen CB, McGrath JJ, et al. Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study. Bipolar Disord 2011; 13:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parboosing R, Bao Y, Shen L, et al. Gestational influenza and bipolar disorder in adult offspring. JAMA Psychiatry 2013; 70:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canetta SE, Bao Y, Co MD, et al. Serological documentation of maternal influenza exposure and bipolar disorder in adult offspring. Am J Psychiatry 2014; 171:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott J, McNeill Y, Cavanagh J, et al. Exposure to obstetric complications and subsequent development of bipolar disorder: Systematic review. Br J Psychiatry 2006; 189:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martelon M, Wilens TE, Anderson JP, et al. Are obstetrical, perinatal, and infantile difficulties associated with pediatric bipolar disorder? Bipolar Disord 2012; 14:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chudal R, Sourander A, Polo-Kantola P, et al. Perinatal factors and the risk of bipolar disorder in Finland. J Affect Disord 2014; 155:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nosarti C, Reichenberg A, Murray RM, et al. Preterm birth and psychiatric disorders in young adult life. Arch Gen Psychiatry 2012; 69:E1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inglis A, Morris E, Austin J. Prenatal genetic counselling for psychiatric disorders. Prenat Diagn 2017; 37:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenstein P, Yip BH, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moskvina V, Craddock N, Holmans P, et al. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 2009; 14:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulze TG, Hedeker D, Zandi P, et al. What is familial about familial bipolar disorder? Resemblance among relatives across a broad spectrum of phenotypic characteristics. Arch Gen Psychiatry 2006; 63:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Schizophrenia Consortium, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birmaher B, Axelson D, Goldstein B, et al. Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS). Am J Psychiatry 2010; 167:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirshfeld-Becker DR, Biederman J, Henin A, et al. Psychopathology in the young offspring of parents with bipolar disorder: a controlled pilot study. Psychiatry Res 2006; 145:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birmaher B, Axelson D, Monk K, et al. Lifetime psychiatric disorders in school-aged offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring study. Arch Gen Psychiatry 2009; 66:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffy A, Horrocks J, Doucette S, et al. The developmental trajectory of bipolar disorder. Br J Psychiatry 2014; 204:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparks GM, Axelson DA, Yu H, et al. Disruptive mood dysregulation disorder and chronic irritability in youth at familial risk for bipolar disorder. J Am Acad Child Adolesc Psychiatry 2014; 53:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sucksdorff D, Chudal R, Suominen A, et al. Bipolar disorder and parental psychopathology. Soc Psychiatry Psychiatr Epidemiol 2014; 49:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mesman E, Nolen WA, Reichart CG, et al. The Dutch bipolar offspring study: 12-year follow-up. Am J Psychiatry 2013; 170:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santucci AK, Singer LT, Wisniewski SR, et al. One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder. J Clin Psychiatry 2017; 78:1083.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15701 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25455249" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25827504" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Unplanned pregnancies and reproductive health among women with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25827504" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Unplanned pregnancies and reproductive health among women with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19277844" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Use of contraceptive methods among women treated for bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32103960" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Impulsivity, Unplanned Pregnancies, and Contraception Among Women with Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27364100" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22105263" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22105263" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24703170" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32980990" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30741085" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Tamoxifen for bipolar disorder: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764379" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20712751" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Metabolic dysfunction in women with bipolar disorder: the potential influence of family history of type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17895237" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mood disorders and fertility in women: a critical review of the literature and implications for future research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30089956" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Bipolar affective disorder and its impact on various aspects of marital relationship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262071" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15465997" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prolactin elevation with ziprasidone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18480684" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Maternal use of antipsychotics in early pregnancy and delivery outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31417404" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Olanzapine-Induced Hyperprolactinemia: Two Case Reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27160812" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33164215" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bipolar disorder: Treatment strategies for women of childbearing age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23247604" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Perinatal episodes across the mood disorder spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30769297" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk of recurrence of mood disorders during pregnancy and the impact of medication: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18056236" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10671384" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34416620" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bipolar episodes after reproductive events in women with bipolar I disorder, A study of 919 pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21799064" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Episodes of mood disorders in 2,252 pregnancies and postpartum periods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18402631" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lamotrigine in bipolar disorder: efficacy during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12044195" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The long-term natural history of the weekly symptomatic status of bipolar I disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12622659" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8498879" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1845226" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9090345" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23137820" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25446660" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Perinatal outcomes among women with bipolar disorder: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23273549" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24102676" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Antibodies to Toxoplasma gondii in individuals with mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22325983" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22085475" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23699867" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Gestational influenza and bipolar disorder in adult offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24480930" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Serological documentation of maternal influenza exposure and bipolar disorder in adult offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816299" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Exposure to obstetric complications and subsequent development of bipolar disorder: Systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22642419" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Are obstetrical, perinatal, and infantile difficulties associated with pediatric bipolar disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24215899" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Perinatal factors and the risk of bipolar disorder in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22660967" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Preterm birth and psychiatric disorders in young adult life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27466037" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prenatal genetic counselling for psychiatric disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19358880" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The genetics of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19150704" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19065143" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17146011" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : What is familial about familial bipolar disorder? Resemblance among relatives across a broad spectrum of phenotypic characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19571811" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20080982" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17083985" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Psychopathology in the young offspring of parents with bipolar disorder: a controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255378" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Lifetime psychiatric disorders in school-aged offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262817" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The developmental trajectory of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24655650" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Disruptive mood dysregulation disorder and chronic irritability in youth at familial risk for bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24791657" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Bipolar disorder and parental psychopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429906" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The Dutch bipolar offspring study: 12-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28068465" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
